Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Houston, Texas
Treatments:Biologic therapyHospital:The University of Texas MD Anderson Cancer Center
Drugs:Journal:Link
Date:Sep 2013

Description:

Patients:
This phase 2 study involved 45 patients with diffuse large B-cell lymphoma, transformed large cell lymphoma, or grade 3 follicular lymphoma. The median patient age was 66 years and 62% were male.

Treatment:
Patients were treated with the biologic therapy agent rituximab (monoclonal antibody for CD20 that directs the immune system to kill cancer cells) and the immunomodulatory (biologic) agent called lenalidomide that interferes with cancer cell growth.

Toxicities:
There was one death due to “natural causes” during the study that may have been due to treatment. Grade 4 neutropenia, thrombocytopenia, and leukopenia were also reported.

Results:
The median overall survival was 10.7 months.

Support:
Some of the authors have received funding from Celgene Corporation.

Correspondence: Dr. M Wang; email: [email protected]



Back